Many cancers upregulate an amino acid transporter to fuel their growth, making this protein a promising tool in tumor ...

T1 Tumor limited to the pancreas and size <2 cm T2 Tumor limited to the pancreas and size 2–4 cm T3 Tumor limited to the pancreas and size >4 cm or invading duodenum or bile duct T4 Tumor ...

TLSs serve as the immune system’s on-site responders, forming in chronically inflamed tissues, including tumors, to bolster ...

Marker also expects to test a six-antigen product candidate, MT-601, in a trial for pancreatic cancer. In addition, the company is advancing its off-the-shelf (OTS) platform through a version of ...

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadly forms of cancer. This means it grows and spreads very quickly, making it difficult to treat.

The latest grant is intended to support the company’s Phase 1 PANACEA study evaluating the safety and tolerability of MT-601 in patients with metastatic pancreatic cancer. Marker Therapeutics ...

Pancreatic cancer kills 50,000 people each year, according to the National Cancer Institute, and there are few effective treatment options for the disease. In a new study, researchers at ...